GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00488136 | Prostate | BPH | dendrite morphogenesis | 45/3107 | 146/18723 | 1.46e-05 | 1.88e-04 | 45 |
GO:00510516 | Prostate | BPH | negative regulation of transport | 113/3107 | 470/18723 | 1.76e-05 | 2.18e-04 | 113 |
GO:00002099 | Prostate | BPH | protein polyubiquitination | 64/3107 | 236/18723 | 2.83e-05 | 3.31e-04 | 64 |
GO:19038287 | Prostate | BPH | negative regulation of cellular protein localization | 36/3107 | 117/18723 | 1.04e-04 | 9.58e-04 | 36 |
GO:00458079 | Prostate | BPH | positive regulation of endocytosis | 32/3107 | 100/18723 | 1.09e-04 | 9.95e-04 | 32 |
GO:00300489 | Prostate | BPH | actin filament-based movement | 38/3107 | 127/18723 | 1.31e-04 | 1.18e-03 | 38 |
GO:00485888 | Prostate | BPH | developmental cell growth | 61/3107 | 234/18723 | 1.46e-04 | 1.29e-03 | 61 |
GO:00459279 | Prostate | BPH | positive regulation of growth | 66/3107 | 259/18723 | 1.64e-04 | 1.43e-03 | 66 |
GO:00030127 | Prostate | BPH | muscle system process | 103/3107 | 452/18723 | 3.54e-04 | 2.62e-03 | 103 |
GO:00605608 | Prostate | BPH | developmental growth involved in morphogenesis | 58/3107 | 234/18723 | 8.28e-04 | 5.40e-03 | 58 |
GO:19901387 | Prostate | BPH | neuron projection extension | 43/3107 | 172/18723 | 3.06e-03 | 1.60e-02 | 43 |
GO:00486388 | Prostate | BPH | regulation of developmental growth | 74/3107 | 330/18723 | 3.43e-03 | 1.76e-02 | 74 |
GO:00065134 | Prostate | BPH | protein monoubiquitination | 20/3107 | 67/18723 | 4.93e-03 | 2.33e-02 | 20 |
GO:0048814 | Prostate | BPH | regulation of dendrite morphogenesis | 20/3107 | 67/18723 | 4.93e-03 | 2.33e-02 | 20 |
GO:000202810 | Prostate | BPH | regulation of sodium ion transport | 25/3107 | 90/18723 | 5.18e-03 | 2.43e-02 | 25 |
GO:190230514 | Prostate | BPH | regulation of sodium ion transmembrane transport | 20/3107 | 68/18723 | 5.92e-03 | 2.73e-02 | 20 |
GO:00860018 | Prostate | BPH | cardiac muscle cell action potential | 21/3107 | 76/18723 | 1.05e-02 | 4.39e-02 | 21 |
GO:004217619 | Prostate | Tumor | regulation of protein catabolic process | 142/3246 | 391/18723 | 9.32e-20 | 5.79e-17 | 142 |
GO:003164719 | Prostate | Tumor | regulation of protein stability | 112/3246 | 298/18723 | 4.18e-17 | 1.18e-14 | 112 |
GO:001049819 | Prostate | Tumor | proteasomal protein catabolic process | 158/3246 | 490/18723 | 3.05e-16 | 6.76e-14 | 158 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0453020 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa05169110 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa04530110 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa04530211 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa04530310 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0453014 | Liver | NAFLD | Tight junction | 33/1043 | 169/8465 | 4.52e-03 | 4.12e-02 | 3.32e-02 | 33 |
hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0453015 | Liver | NAFLD | Tight junction | 33/1043 | 169/8465 | 4.52e-03 | 4.12e-02 | 3.32e-02 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NEDD4 | SNV | Missense_Mutation | novel | c.3618N>G | p.Asp1206Glu | p.D1206E | P46934 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
NEDD4 | SNV | Missense_Mutation | | c.3271N>G | p.His1091Asp | p.H1091D | P46934 | protein_coding | deleterious(0.03) | benign(0.05) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NEDD4 | SNV | Missense_Mutation | rs547250575 | c.280G>A | p.Glu94Lys | p.E94K | P46934 | protein_coding | deleterious(0.05) | probably_damaging(0.965) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEDD4 | SNV | Missense_Mutation | | c.1361N>A | p.Arg454Gln | p.R454Q | P46934 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
NEDD4 | SNV | Missense_Mutation | | c.2611C>T | p.Pro871Ser | p.P871S | P46934 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
NEDD4 | SNV | Missense_Mutation | novel | c.154N>T | p.Met52Leu | p.M52L | P46934 | protein_coding | tolerated(0.3) | benign(0) | TCGA-E2-A576-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
NEDD4 | SNV | Missense_Mutation | rs369468383 | c.358G>T | p.Asp120Tyr | p.D120Y | P46934 | protein_coding | deleterious_low_confidence(0) | benign(0.347) | TCGA-GM-A2DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD |
NEDD4 | SNV | Missense_Mutation | novel | c.3895G>C | p.Glu1299Gln | p.E1299Q | P46934 | protein_coding | tolerated(0.13) | benign(0.125) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEDD4 | insertion | Frame_Shift_Ins | novel | c.2747_2748insCCCTGTCTCTACTAAAAATGCAAAAAAAATTAGTTGGG | p.Lys916AsnfsTer26 | p.K916Nfs*26 | P46934 | protein_coding | | | TCGA-BH-A0H9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
NEDD4 | insertion | Frame_Shift_Ins | novel | c.38_39insGATATTCTTGTGTTTCAGTGCATTTG | p.Ser14IlefsTer45 | p.S14Ifs*45 | P46934 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |